The market for cyclin-dependent kinases (CDK) 4/6 inhibitors that are used to treat metastatic breast cancer have undergone drastic changes last year. Sales of Ibrance, which used to dominate the market, had faltered, while the latecomer Kisqali rapidly expanded its share in the market .

According to the market research institution IQVIA on the 8th, the domestic market for CDK 4/6 inhibitors increased 7.1% YoY from KRW 86.5 billion in the previous year to ₩92.6 billion last year.

CDK, cyclin-dependent kinases, control cell division and growth. CDK 4/6 inhibitors selectively inhibit CDK 4/6 to suppress the proliferation of cancer cells. These drugs are mainly used to treat hormone r